RecruitingPhase 1NCT06808477

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD

Sponsor

Bambusa Therapeutics

Enrollment

237 participants

Start Date

Feb 27, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Eligibility

Min Age: 18 YearsMax Age: 72 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BBT001 and a drug called Placebo for people with atopic dermatitis. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBBT001

BBT001 will be administered

DRUGPlacebo

Placebo will be administered

Locations(14)

First OC Dermatology

Irvine, California, United States

OptiSkin Medical

New York, New York, United States

Equity Medical, LLC

The Bronx, New York, United States

Fremantle Dermatology

Fremantle, Western Australia, Australia

Linear Clinical Research

Perth, Western Australia, Australia

Optimal Clinical Trials Central Auckland

Grafton, Auckland, New Zealand

Aotearoa Clinical Trials

Otahuhu, Auckland, New Zealand

Pacific Clinical Research Network (PCRN) - Auckland

Takapuna, Auckland, New Zealand

Optimal Clinical Trials Ltd - Christchurch

Christchurch, Christchurch, New Zealand

Pacific Clinical Research Network (PCRN) Wellington

Upper Hutt, New Zealand

Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi

Lodz, Poland

Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie

Rzeszów, Poland

Państwowy Instytut Medyczny MSWiA

Warsaw, Poland

Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

Wroclaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06808477

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897148 locations

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT060968571 location

Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children

NCT044195841 location

The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis

NCT074675647 locations